Woodcock to CDER as Galson named acting surgeon general

Share this article:
Dr. Janet Woodcock will assume the role of acting director of the Center for Drug Evaluation and Research (CDER) as the center's previous director, Dr. Steven Galson, becomes acting surgeon general.

Woodcock will retain her position as deputy commissioner and permanent chief medical officer, and will work with FDA Commissioner Andrew von Eschenbach to launch a national search for a permanent director of the center, the FDA said.

Of Galson, von Eschenbach said: "Because of his accomplishments, Americans have access to safer and more effective medical products than ever before. I know Steven will excel as our nation's chief health educator and Americans will continue to benefit from his dedication to public service."
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...